Analyst Viewpoint
Increase in prevalence of cancer is one of the prominent factors driving the targeted therapeutics industry. Targeted therapeutics result in alteration of proteins in cancer cells, thus causing their death.
They also prevent the formation of new cells, thereby cutting off blood supply to tumor, and deliver toxins that act as predators to cancer cells without causing any harm to healthy cells. Rise in awareness programs regarding the benefits of targeted therapeutics is also contributing to targeted therapeutics market growth.
Companies operating in the global targeted therapeutics industry are exploring the adoption of new approaches such as synthetic biology, which harnesses the immune system with greater precision.
Leading players are closely observing the latest targeted therapeutics market trends and embracing advanced and innovative technologies to develop precision medicines of the future.
Targeted therapeutics, a type of cancer treatment, refers to the usage of drugs for targeting specific proteins and genes that help in the proliferation of cancer cells. These therapeutics can be used either solitarily or in combination with chemotherapy.
Currently, targeted therapeutics are not available for all types of cancers. However, it remains a vast arena to be explored. Several targeted therapies are in the pipeline.
The ongoing trend is that of deploying precision medicines for cancer treatment. Targeted therapeutics use specific information about the patient’s tumor for helping in diagnosis, treatment, and prognosis.
In other words, personalized molecular therapies enable clinicians to work out individual vulnerability as a response to infection. These therapies can also gauge the inter-individual heterogeneity.
Biomarker-guided therapeutic approaches are gaining traction across the globe, as biomarkers help in facilitating adaptive clinical trial designs. These designs can be used to measure the effects of drug treatment in patients throughout trial, including toxicity responses and clinical efficacy.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Air pollution and adoption of unhealthy habits are some of the factors that may cause cancer. For instance, smoking and excessive consumption of alcohol can result in cancers of the lung and lever. Chewing of tobacco is reported to cause oral cancer.
The WHO states that around 1.3 billion people consume tobacco products across the globe; of these, 80% people belong to middle- and low-income countries.
As per the WHO’s International Agency for Research on Cancer (IARC), the year 2022 witnessed 20 million novel cancer cases. It further states that 20% of the global population develops cancer in their lifetime.
Other findings state that lung cancer is the most prevalent, followed by breast cancer, colorectal cancer, prostate cancer, and stomach cancer. Certain countries in sub-Saharan Africa also witnessed the onslaught of cervical cancer in 2022.
This surge in prevalence of various types of cancers worldwide is driving the targeted therapeutics industry growth.
As per the WHO, 34 million new cases of cancer are likely to be diagnosed by 2050, a 77% increase compared to that in 2022. This number can be brought under control through regular awareness campaigns regarding the prevalence of cancer.
In 2020, 194 countries aligned with the WHO’s global strategy aimed toward elimination of cervical cancer worldwide. Such initiatives are boosting the demand for targeted therapeutics worldwide.
In 2021, ‘Let’s demask cancer,’ a web platform, launched an exclusive website with information and a comic book. The website stresses upon the importance of early diagnosis of colon cancer and also highlights personalized therapeutics.
Research states that colorectal cancer takes five to 10 years to transform from benign to a malignant one. If detected early, customized therapies can be applied and the lives of patients can be saved.
Thus, growth in awareness campaigns regarding the importance of targeted therapeutics in cancer is augmenting the targeted therapeutics market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the targeted therapeutics market analysis, demand for individualized gene therapy solutions was high in North America in 2022. This trend is anticipated to continue during the forecast period.
Large targeted therapeutics market share of North America can be ascribed to the high incidence of cancer in the region. As per the American Cancer Society, the number of new cancer cases in the U.S. stood at 1.95 million in 2023. According to Statistics Canada, there were 233,900 cases of cancer in 2022.
Europe and Asia Pacific also recorded substantial market progress in 2022. According to the OECD, the year 2022 witnessed 2.74 million new cases of cancer in the 27 EU member states. This number is expected to rise by 2% to 3% every year.
On the other hand, Southeast Asia reported 2.2 million new cases of cancer and 1.4 million cancer-related fatalities in 2020, as per the WHO. Thus, the targeted therapeutics market forecast appears positive in Europe and Asia Pacific.
Companies operating in the global targeted therapeutics landscape are focusing on launching new products and obtaining quick product approvals. Prompt response by the regulatory bodies regarding product approval is enabling companies to expand their product portfolio.
In May 2021, the U.S.FDA approved Janssen’s Rybrevant (amivantamab), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., and Bristol-Myers Squibb Company are some of the key players covered in the targeted therapeutics market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 69.8 Bn |
| Market Forecast (Value) in 2031 | US$ 118.6 Bn |
| Growth Rate (CAGR) | 6.4% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 69.8 Bn in 2022
It is projected to grow at a CAGR of 6.4% from 2023 to 2031
Growth in incidence of cancer and rise in awareness campaigns regarding cancer therapeutics
The hospital pharmacies segment accounted for the largest share in 2022
North America was the dominant region in 2022
Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., and Bristol-Myers Squibb Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Targeted Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Targeted Therapeutics Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.1.1. Angiogenesis Inhibitors
6.3.1.2. HER-2 Targeted Agents
6.3.1.3. Anti-CD20 Monoclonal Antibodies
6.3.2. Small Molecule
6.3.2.1. Tyrosine Kinase Inhibitors
6.3.2.1.1. mTOR Inhibitors
6.3.2.1.2. PARP Inhibitors
6.4. Market Attractiveness Analysis, by Type
7. Global Targeted Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Colorectal Cancer
7.3.3. Leukemia
7.3.4. Lung Cancer
7.3.5. Lymphoma
7.3.6. Multiple Sclerosis
7.3.7. Renal Cancer
7.3.8. Wet Age-related Macular Degeneration
7.3.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate Cancer, and Pancreatic Cancer)
7.4. Market Attractiveness Analysis, by Application
8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Targeted Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Targeted Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Monoclonal Antibodies
10.3.1.1. Angiogenesis Inhibitors
10.3.1.2. HER-2 Targeted Agents
10.3.1.3. Anti-CD20 Monoclonal Antibodies
10.3.2. Small Molecule
10.3.2.1. Tyrosine Kinase Inhibitors
10.3.2.1.1. mTOR Inhibitors
10.3.2.1.2. PARP Inhibitors
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Breast Cancer
10.4.2. Colorectal Cancer
10.4.3. Leukemia
10.4.4. Lung Cancer
10.4.5. Lymphoma
10.4.6. Multiple Sclerosis
10.4.7. Renal Cancer
10.4.8. Wet Age-related Macular Degeneration
10.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Application
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Targeted Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Monoclonal Antibodies
11.3.1.1. Angiogenesis Inhibitors
11.3.1.2. HER-2 Targeted Agents
11.3.1.3. Anti-CD20 Monoclonal Antibodies
11.3.2. Small Molecule
11.3.2.1. Tyrosine Kinase Inhibitors
11.3.2.1.1. mTOR Inhibitors
11.3.3. 11.3.2.1.2 PARP Inhibitors
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Breast Cancer
11.4.2. Colorectal Cancer
11.4.3. Leukemia
11.4.4. Lung Cancer
11.4.5. Lymphoma
11.4.6. Multiple Sclerosis
11.4.7. Renal Cancer
11.4.8. Wet Age-related Macular Degeneration
11.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Application
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Monoclonal Antibodies
12.3.1.1. Angiogenesis Inhibitors
12.3.1.2. HER-2 Targeted Agents
12.3.1.3. Anti-CD20 Monoclonal Antibodies
12.3.2. Small Molecule
12.3.2.1. Tyrosine Kinase Inhibitors
12.3.2.1.1. mTOR Inhibitors
12.3.2.1.2. PARP Inhibitors
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Leukemia
12.4.4. Lung Cancer
12.4.5. Lymphoma
12.4.6. Multiple Sclerosis
12.4.7. Renal Cancer
12.4.8. Wet Age-related Macular Degeneration
12.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Application
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Targeted Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Monoclonal Antibodies
13.3.1.1. Angiogenesis Inhibitors
13.3.1.2. HER-2 Targeted Agents
13.3.1.3. Anti-CD20 Monoclonal Antibodies
13.3.2. Small Molecule
13.3.2.1. Tyrosine Kinase Inhibitors
13.3.2.1.1. mTOR Inhibitors
13.3.2.1.2. PARP Inhibitors
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Breast Cancer
13.4.2. Colorectal Cancer
13.4.3. Leukemia
13.4.4. Lung Cancer
13.4.5. Lymphoma
13.4.6. Multiple Sclerosis
13.4.7. Renal Cancer
13.4.8. Wet Age-related Macular Degeneration
13.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Application
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Monoclonal Antibodies
14.3.1.1. Angiogenesis Inhibitors
14.3.1.2. HER-2 Targeted Agents
14.3.1.3. Anti-CD20 Monoclonal Antibodies
14.3.2. Small Molecule
14.3.2.1. Tyrosine Kinase Inhibitors
14.3.2.1.1. mTOR Inhibitors
14.3.2.1.2. PARP Inhibitors
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Breast Cancer
14.4.2. Colorectal Cancer
14.4.3. Leukemia
14.4.4. Lung Cancer
14.4.5. Lymphoma
14.4.6. Multiple Sclerosis
14.4.7. Renal Cancer
14.4.8. Wet Age-related Macular Degeneration
14.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Application
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Sanofi
15.3.1.1. Company Overview
15.3.1.2. Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview
15.3.2.2. Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Takeda Pharmaceutical Company Ltd.
15.3.3.1. Company Overview
15.3.3.2. Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview
15.3.5.2. Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview
15.3.7.2. Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. AstraZeneca
15.3.8.1. Company Overview
15.3.8.2. Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Seagen, Inc.
15.3.9.1. Company Overview
15.3.9.2. Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bayer AG
15.3.10.1. Company Overview
15.3.10.2. Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Amgen, Inc.
15.3.11.1. Company Overview
15.3.11.2. Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Bristol-Myers Squibb Company
15.3.12.1. Company Overview
15.3.12.2. Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
List of Tables
Table 01: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Targeted Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Targeted Therapeutics Market Revenue (US$ Mn), by Type, 2022
Figure 03: Global Targeted Therapeutics Market Value Share, by Type, 2022
Figure 04: Global Targeted Therapeutics Market Revenue (US$ Mn), by Application, 2022
Figure 05: Global Targeted Therapeutics Market Value Share, by Application, 2022
Figure 06: Global Targeted Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Targeted Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 08: Global Targeted Therapeutics Market Value Share, by Region, 2022
Figure 09: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 11: Global Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 12: Global Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 13: Global Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 14: Global Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 15: Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 16: Global Targeted Therapeutics Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Targeted Therapeutics Market Attractiveness Analysis, by Region, 2023–2031
Figure 18: North America Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Targeted Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Targeted Therapeutics Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 22: North America Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 23: North America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 25: North America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 26: North America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 31: Europe Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 32: Europe Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 34: Europe Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 35: Europe Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 40: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 41: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 43: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 44: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 49: Latin America Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 50: Latin America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 52: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 53: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031
Figure 58: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031
Figure 59: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031
Figure 61: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031
Figure 62: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Targeted Therapeutics Market
*86 figures and 60 tables includes